AstraZeneca PLC (LON:AZN) Receives GBX 6,303.50 Consensus Price Target from Analysts

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is GBX 6,303.50 ($83.63).

Several analysts have recently weighed in on AZN shares. Berenberg Bank reiterated a "buy" rating and set a GBX 140 ($1.86) target price on shares of AstraZeneca in a research report on Wednesday, March 26th. JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Finally, Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a research report on Friday, March 7th.

AstraZeneca Trading Down 1.3 %

Shares of AZN stock traded down GBX 130 ($1.72) on Tuesday, reaching £101.24 ($134.32). 3,289,064 shares of the company's stock were exchanged, compared to its average volume of 19,465,084. The company's fifty day simple moving average is £113.41 and its 200 day simple moving average is £110.81. AstraZeneca has a 52 week low of GBX 9,573.51 ($127.02) and a 52 week high of £133.88 ($177.63). The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market capitalization of £194.79 billion, a PE ratio of 27.75, a P/E/G ratio of 0.86 and a beta of 0.17.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.